XOLEGEL- ketoconazole gel
Stiefel Laboratories Inc
XOLEGEL Gel contains the antifungal agent ketoconazole USP at 2% in a topical anhydrous gel vehicle.
Chemically ketoconazole is (±)-cis-1-Acetyl-4-[p-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine, with a molecular weight of 531.43.
Each gram contains: 20 mg ketoconazole USP, 34% dehydrated alcohol USP, ascorbic acid USP, butylated hydroxytoluene NF, citric acid monohydrate USP, glycerin USP, hydroxypropyl cellulose NF, polyethylene glycol 400 NF, PPG-15 stearyl ether, propylene glycol USP, FD&C yellow No. 6, D&C yellow No. 10
XOLEGEL Gel is a smooth, translucent to clear, amber gel.
The contribution to efficacy of individual components of the vehicle has not been established.
In a pharmacokinetic absorption study, eighteen subjects, both males and females, with severe seborrheic dermatitis (range 1-14% of body surface area) applied XOLEGEL Gel once daily for 2 weeks. The median total amount of gel applied was 4.6 g (range 1.65–46.3 g). Daily doses ranged from 0.05 to 3.47 g. Mean (± standard deviation [SD]) peak plasma levels were 1.35 (± 3.18) ng/mL on Day 7 (range from <0.1 ng/mL to 13.9 ng/mL), and 0.80 (± 1.22) ng/mL on Day 14 (range from <0.1 ng/mL to 5.4 ng/mL). Median Tmax was 8 hours on Day 7 and 7 hours on Day 14. Mean (± SD) AUC0-24 values were 20.8 (± 44.7) ng•h/mL and 15.6 (± 26.4) ng•h/mL on Day 7 and 14, respectively.
The plasma levels from an oral dose of 200 mg ketoconazole taken with a meal are approximately 250 times higher than the resulting plasma levels of ketoconazole following topical application of XOLEGEL Gel.
Ketoconazole is an antifungal agent which, in vitro, inhibits the synthesis of ergosterol, a key sterol in the cell membrane of Malassezia furfur (also known as Pityrosporum ovale), which leads to the death of the organism.
Study 1 was a multicenter, double-blind, randomized, vehicle-controlled trial which enrolled 459 patients 12 years of age and older with moderate to severe seborrheic dermatitis. A total of 229 patients were treated with XOLEGEL Gel, and 230 patients were treated with vehicle. All patients were treated once daily for 14 days, and efficacy was assessed at Day 28 (i.e., 2 weeks after end of treatment). Effective Treatment was defined as:
The proportion of patients effectively treated is shown in the following table.
Proportion of patients effectively treated
|58 (25.3%)||32 (13.9%)|
Two additional double-blind, randomized, vehicle-controlled, parallel, and multi-center studies that included a total of 316 patients treated with XOLEGEL Gel provided supportive evidence of the efficacy of XOLEGEL Gel for treatment of seborrheic dermatitis. Patients applied either XOLEGEL Gel or vehicle study treatment to the affected area(s) once daily for 14 days and were followed through Day 28. Efficacy was assessed by the proportion of patients who were completely clear at Day 28.
XOLEGEL Gel is indicated for the topical treatment of seborrheic dermatitis in immunocompetent adults and children 12 years of age and older.
Safety and efficacy of XOLEGEL Gel for treatment of fungal infections have not been established.
XOLEGEL Gel is contraindicated in those patients with a history of sensitivity reactions to any of its components. It should be discontinued if hypersensitivity is noted.
XOLEGEL Gel is for topical use only, and not for ophthalmic, oral or intravaginal use. If irritation occurs or if the disease worsens, use of the medication should be discontinued, and the health care provider should be contacted.
Hepatitis and, at high doses, lowered testosterone and ACTH induced corticosteroid serum levels have been seen with orally administered ketoconazole; these effects have not been seen with topical ketoconazole.
Long-term studies to assess the carcinogenic potential of XOLEGEL Gel have not been conducted. A long-term feeding study in Swiss Albino mice and in Wistar rats showed no evidence of oncogenic activity. Ketoconazole gel at a dosage up to 5 mg/kg/dose is not photocarcinogenic when topically applied to hairless mice five days per week for a period of 40 weeks. Ketoconazole produced no evidence of mutagenicity in the dominant lethal mutation test in male and female mice at single oral doses up to 80 mg/kg. When tested in the Ames assay, ketoconazole was found to be non-mutagenic to Salmonella typhimurium in the presence and absence of metabolic activation. Ketoconazole, in combination with another drug, gave equivocal results in the mouse micronucleus test. At oral doses of 75 to 80 mg/kg/day (71 to 76 times the human dose) ketoconazole impaired the reproductive performance in female (decreased pregnancy and implantation rates) and male (increased abnormal sperm and decreased sperm motility) rats.
Reproductive toxicity studies have not been performed with XOLEGEL Gel. Ketoconazole was tested for its effects on offspring in the rat at oral doses of 10, 20, 40, 80, and 160 mg/kg. Ketoconazole was teratogenic (syndactylia and oligodactylia) at 80 mg/kg/day and embryotoxic at 160 mg/kg/day (76 and 152 times the human dose, respectively). However, these effects may be related to maternal toxicity, which was also seen at these dose levels.
Oral doses of 10, 20, 40, 80 and 160 mg/kg were studied in pre- and postnatal development studies in rats. Doses of 40 mg/kg (38 times the human dose) and above were associated with maternal toxicity, an increase in the length of gestation, and an increase in the number of stillborn fetuses. These doses of ketoconazole were also toxic to the offspring, resulting in a decrease in fetal/pup weights and viability.
There are no adequate and well controlled studies in pregnant women. XOLEGEL Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether XOLEGEL Gel is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when XOLEGEL Gel is administered to a nursing woman.
Safety and effectiveness in pediatric patients below the age of 12 have not been established.
Of the 933 subjects in the three safety and efficacy studies, 193 (20.7%) were 65 and over, while 61 (6.5%) were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects but greater sensitivity of some older individuals cannot be ruled out.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.
Overall Summary of Adverse Events Reported by >1% of Subjects
NOTE: The same adverse event recorded by a subject at different visits count as one event for that subject, and the strongest intensity and relationship to treatment is used. At each level of summarization (System Organ Class and Preferred Term) subjects are only counted once.
|Any Adverse Event||89 (16.3)||67 (17.3)|
|Application site burning||23 (4.2)||12 (3.1)|
|Headache||6 (1.1)||3 (0.8)|
In the three safety and efficacy studies, 65 of 933 subjects (7%) experienced at least one treatment-related adverse event. The most common treatment-related adverse event was application site burning (see Table 2). Treatment-related application site reactions that were reported in < 1% of subjects were: dermatitis, discharge, dryness, erythema, irritation, pain, pruritus, and pustules. Other treatment-related adverse reactions that were reported in < 1% of subjects were: eye irritation, eye swelling, keratoconjunctivitis sicca, impetigo, pyogenic granuloma, dizziness, headache, paresthesia, acne, nail discoloration, facial swelling.
Contact sensitization, cumulative irritation, phototoxicity and photoallergy studies were conducted with XOLEGEL Gel. Under the conditions of study, XOLEGEL Gel did not demonstrate contact sensitization, phototoxicity or photoallergenicity, but did demonstrate potential to cause irritation.
XOLEGEL Gel is intended for topical use only.
There has been no experience of overdose with XOLEGEL Gel. No incidents of accidental ingestion have been reported. A health care provider or poison control center should be contacted in the event of accidental ingestion.
XOLEGEL Gel should be applied once daily to the affected area for 2 weeks.
XOLEGEL (ketoconazole, USP) Gel, 2% is supplied in the following size tubes:
2-gram sample tube (NDC 13478-003-02)
15-gram aluminum tube (NDC 13478-003-01)
45-gram aluminum tube (NDC 13478-003-05)
Store at 25°C (77°F); excursions permitted to 15° - 30°C (59° - 86°F)
Keep out of reach of children.
DPT Laboratories, Ltd.
307 E. Josephine Street
San Antonio, TX 78215
Barrier Therapeutics, Inc.
600 College Road East
Princeton, NJ 08540-6697
US Patent Numbers: 7,179,475 and application 10/722,134 (Patent Pending)
(Ketoconazole, USP) Gel, 2%
Read the Patient Information that comes with XOLEGEL Gel carefully before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your health care provider. If you have any questions about XOLEGEL Gel, ask your health care provider.
XOLEGEL Gel is a prescription medicine used on the skin (topical) to treat a condition called seborrheic dermatitis. Patients with seborrheic dermatitis can have areas of dry, flaky skin (scales) on the scalp, face, ears, chest, or upper back.
XOLEGEL Gel has not been studied in children below the age of 12.
What should I tell my health care provider before using XOLEGEL Gel?
Tell your health care provider about all of the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. It is not known if XOLEGEL Gel and other medicines can affect each other.
How should I use XOLEGEL Gel?
What should I avoid while using XOLEGEL Gel?
What are the possible side effects of XOLEGEL Gel?
These are not all of the side effects of XOLEGEL Gel. For more information, ask your health care provider or pharmacist.
How should I store XOLEGEL Gel?
General information about XOLEGEL Gel
Medicines are sometimes prescribed for conditions that are not mentioned in Patient Information leaflets. Do not use XOLEGEL Gel for a condition for which it was not prescribed. Do not give XOLEGEL Gel to other people, even if they have the same symptoms that you have. It may harm them.
This Patient Information leaflet summarizes the most important information about XOLEGEL Gel. If you would like more information, talk with your health care provider. You can ask your pharmacist or health care provider for information about XOLEGEL Gel that is written for health professionals. For additional information on XOLEGEL Gel visit www.XOLEGEL.com or call Barrier Therapeutics, Inc. customer service at 1-866-440-5508.
What are the ingredients in XOLEGEL Gel?
Active ingredient: ketoconazole
Inactive ingredients: dehydrated alcohol USP, ascorbic acid USP, butylated hydroxytoluene NF, citric acid monohydrate USP, glycerin USP, hydroxypropyl cellulose NF, polyethylene glycol 400 NF, PPG-15 stearyl ether, propylene glycol USP, FD&C yellow No. 6, D&C Yellow No. 10.
|Labeler - Stiefel Laboratories Inc (808842343)|